National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Appendix 26: Streptococcus pneumoniae." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
322
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

CDC. Pneumococcal and Influenza Vaccination Levels Among Adults Aged Over 65 Years—United States, 1995. Morbidity and Mortality Weekly Report 1997; 46:913–926.

CDC. Prevention of Pneumococcal Disease. Morbidity and Mortality Weekly Report 1997; 46:1–24.


Fedson DS. Pneumococcal Vaccination in the Prevention of Community-Acquired Pneumonia: An Optimistic View of Cost-Effectiveness. Seminars in Respiratory Infections 1993; 8:285–293.

Fedson DS, Shapiro ED, LaForce FM, et al. Pneumococcal Vaccine After 15 Years of Use—Another View. Archives of Internal Medicine; 154:2531–2535.


Institute for Advanced Studies in Immunology and Aging. Improving the Performance of Influenza and Pneumococcal Vaccines in Adults. Working Group Meeting—November 1995; Washington, DC.


King JC, Vink PE, Farley JJ, et al. Safety and Immunogenicity of Three Doses of a Five-Valent Pneumococcal Conjugate Vaccine in Children Younger Than Two Years With and Without Human Immunodeficiency Virus Infection. Pediatrics 1997; 99:575–580.

Kronenberger CB, Hoffman RE, Lezotte DC, et al. Invasive Penicillin-Resistant Pneumococcal Infections: A Prevalence and Historical Cohort Study. Emerging Infectious Diseases 1996; 2:121–124.


Lave JR, Fine MJ, Sankey SS, et al. Hospitalized Pneumonia—Outcomes, Treatment Patterns, and Costs in Urban and Rural Areas. Journal of General Internal Medicine 1996; 11:415–421.

Loughlin AM, Marchant CD, Lett SM. The Changing Epidemiology of Invasive Bacterial Infections in Massachusetts Children, 1984 through 1991. American Journal of Public Health 1995; 85:392–394.


Markowitz JS, Pashko S, Gutterman EM, et al. Death Rates among Patients Hospitalized with Community-Acquired Pneumonia: A Reexamination with Data from Three States . American Journal of Public Health 1996; 86:1152–1154.


Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of Vaccination Against Pneumococcal Bacteremia Among Elderly People. JAMA 1997; 278:1333–1339.


Tuomanen EI, Austrian R, Masure HR. Pathogenesis of Pneumococcal Infection. The New England Journal of Medicine 1995; 332:1280.


U.S. Bureau of the Census. Statistical Abstract of the U.S.: 1995 (115th edition). Washington, DC, 1995.


Wenger JD, Hightower AW, Facklam RR, et al. Bacterial Meningitis in the United States, 1986: Report of a Multistate Surveillance Study. The Journal of Infectious Diseases 1990; 162:1316–1323.

Page
322
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)